uniQure (NASDAQ:QURE) Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. cut its stake in shares of uniQure (NASDAQ:QURE) by 0.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 742,162 shares of the biotechnology company’s stock after selling 2,754 shares during the quarter. uniQure makes up 3.0% of Privium Fund Management B.V.’s portfolio, making the stock its 8th largest holding. Privium Fund Management B.V.’s holdings in uniQure were worth $13,107,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Twin Tree Management LP bought a new position in uniQure during the 4th quarter valued at about $77,000. Monaco Asset Management SAM bought a new position in shares of uniQure in the fourth quarter valued at approximately $2,414,000. Raymond James Financial Inc. bought a new stake in uniQure during the 4th quarter worth approximately $1,951,000. Oppenheimer & Co. Inc. bought a new stake in uniQure during the 4th quarter worth approximately $320,000. Finally, Palumbo Wealth Management LLC acquired a new stake in uniQure during the 4th quarter valued at $437,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Activity

In other news, CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the sale, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This represents a 8.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock valued at $961,401 in the last 90 days. 4.74% of the stock is owned by company insiders.

uniQure Price Performance

Shares of QURE stock opened at $13.31 on Wednesday. The firm’s 50 day moving average price is $13.86 and its two-hundred day moving average price is $10.36. The stock has a market cap of $719.76 million, a PE ratio of -2.68 and a beta of 0.36. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

Analyst Ratings Changes

QURE has been the topic of several research analyst reports. Cantor Fitzgerald increased their target price on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. The Goldman Sachs Group increased their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Wells Fargo & Company dropped their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Mizuho upped their target price on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. Finally, Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.